Gapping down
In reaction to earnings/guidance:
- AVAH -13.9%, ZEV -13.4%, CONN -12%, PLAY -5.4%, LIDR -4.3%, DTC -1.6%
Other news:
- NEO -31.5% (CEO steps down, co lowers Q1 revenue and EBITDA guidance)
- LPCN -17.6% (FDA approves Antares Pharma's (ATRS) TLANDO (testosterone undecanoate) oral treatment for testosterone replacement therapy; commercial launch expected in 2Q 2022)
- CGEM -5% (provides clinical update for CLN-081)
- NBIX -3.8% (collaboration partner receives regulatory approval for Dysval in Japan)
- SWX -3.5% (prices offering of 5.5 mln shares of common stock at $74.00 per share)
Analyst comments:
- REAL -4.1% (downgraded to Neutral from Outperform at Credit Suisse)
- BHG -4% (downgraded to Neutral from Overweight at JP Morgan)
- PINS -2.7% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- ETSY -1.9% (downgraded to Hold from Buy at Loop Capital)
- CVS -1.5% (downgraded to Hold from Buy at Deutsche Bank)